MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) announced the launch of Intox AI(TM), an enterprise software platform that uses voice analysis and artificial intelligence to detect cocaine, cannabis, alcohol, narcotics, psychedelics, and human fatigue. The company is preparing to deploy the software through Edge AI kiosk systems, with prototypes expected to be completed in the current quarter, as reported in a news release (https://ibn.fm/GrITB).
The platform analyzes speech patterns in real time to identify indicators of substance use and fatigue. MindBio is targeting commercialization opportunities in mining, aviation, construction, transportation, and law enforcement markets, where safety-critical operations demand reliable and non-invasive testing methods. Intox AI offers an affordable alternative to traditional drug and alcohol testing, which often requires invasive sample collection or expensive equipment.
The launch represents a key step in MindBio's transition from research and clinical development toward commercial implementation. The company has been developing Intox AI to address the need for rapid, accurate, and non-invasive screening in industries where impairment can lead to catastrophic accidents. By leveraging voice analysis, the technology can provide results without requiring specialized training or laboratory analysis.
MindBio's technology is designed to detect multiple substance categories, including those that are often difficult to identify through conventional methods. The inclusion of fatigue assessment is particularly relevant for industries with shift work or long hours, where fatigue can impair performance as severely as alcohol or drugs. The Edge AI kiosk approach allows for decentralized deployment, enabling on-site testing at entry points or workstations.
The company's move toward commercialization follows a period of research and development, with the current quarter's prototype completion expected to pave the way for pilot programs and initial sales. MindBio is positioning Intox AI as a scalable solution that can be integrated into existing workplace safety protocols.
For investors and industry observers, the launch signals MindBio's entry into the growing market for AI-driven safety technologies. The company's focus on non-invasive methods could appeal to employers seeking to reduce costs and improve worker acceptance. Additional information is available in the company's newsroom (https://ibn.fm/MBQIF).
